Niagen Bioscience Doubles Share Repurchase Authorization to $20M

Niagen Bioscience ( (NAGE) ) has shared an update.

On March 19, 2026, Los Angeles-based Niagen Bioscience, a specialist in NAD+ science and healthy-aging supplements and IV therapies, said its board doubled the size of its share repurchase authorization to $20 million of common stock from the $10 million program approved in 2025. The move follows approximately $2.6 million of stock buybacks completed through March 17, 2026, and signals continued confidence in the company’s long-term strategy and perceived undervaluation.

The expanded program, which runs through October 31, 2027 unless changed by the board, allows Niagen to buy shares on the open market or via privately negotiated transactions, including under a potential trading plan. While the company is not obligated to repurchase a specific amount, the increased capacity provides management with additional flexibility to return capital to shareholders and potentially support the stock in volatile market conditions.

Management highlighted that the enlarged repurchase authorization is intended to take advantage of what it sees as a disconnect between Niagen’s market valuation and the fundamentals of its NAD+-focused business. For investors, the decision underscores the board’s willingness to deploy balance sheet resources toward shareholder returns while maintaining optionality to adapt the pace of buybacks to market, regulatory, and corporate needs.

The most recent analyst rating on (NAGE) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Niagen Bioscience stock, see the NAGE Stock Forecast page.

Spark’s Take on NAGE Stock

According to Spark, TipRanks’ AI Analyst, NAGE is a Neutral.

The score is driven primarily by strong underlying fundamentals (profitability turnaround and a very conservative balance sheet) and a constructive earnings update with continued growth guidance. This is meaningfully offset by weak technicals (downtrend versus key moving averages and negative MACD) and only moderate valuation support at ~29x earnings, plus risks from slowing growth, rising spend, and competitive/regulatory uncertainty.

To see Spark’s full report on NAGE stock, click here.

More about Niagen Bioscience

Niagen Bioscience, Inc., formerly ChromaDex Corp., is a NAD+ science and healthy-aging company that develops NAD+-boosting solutions, including its patented nicotinamide riboside ingredient Niagen. The company sells its flagship Tru Niagen consumer supplement, as well as Niagen Plus pharmaceutical-grade intravenous and injectable products through FDA-registered 503B outsourcing facilities and clinics in the United States.

Positioning itself as a global leader in NAD+ research, Niagen Bioscience collaborates with academic and clinical institutions worldwide to study the role of NAD+ in aging and healthspan. The company leverages a robust patent portfolio protecting nicotinamide riboside and other NAD+ precursors, underpinning its competitive moat in the growing longevity and healthy-aging market.

Niagen emphasizes rigorous scientific and quality standards in its state-of-the-art laboratories, seeking to differentiate its offerings from competing dietary supplements. Its Tru Niagen supplement is billed as the leading NAD+ boosting oral product in the U.S. by revenue on the largest e-commerce marketplace for 2024, underscoring its consumer traction in the health and wellness sector.

Average Trading Volume: 1,213,035

Technical Sentiment Signal: Sell

Current Market Cap: $364.4M

Find detailed analytics on NAGE stock on TipRanks’ Stock Analysis page.